Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND1 | P24385 | 20/20 | 0.67 |
| ▸ | CDK4 | P11802 | 19/20 | 0.67 |
| ▸ | CCND2 | P30279 | 9/20 | 0.67 |
| ▸ | CCND3 | P30281 | 9/20 | 0.67 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.66 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.66 |
| ▸ | FGFR4 | P22455 | 5/20 | 0.66 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.66 |
| ▸ | CDK2 | P24941 | 7/20 | 0.57 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.57 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.57 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.57 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4832832 | 1.00 | CCND1 (0.67) | CCND1CDK4CCND2CCND3FGFR1 | |
| SCHEMBL4833230 | 0.92 | CCND1 (0.68) | CCND1CDK4CCND2CCND3FGFR1 | |
| SCHEMBL30176572 | 0.92 | CCND1 (0.68) | CCND1CDK4CCND2CCND3FGFR1 | |
| SCHEMBL30176591 | 0.91 | CDK4 (0.71) | CCND1CDK4CCND2CCND3FGFR1 | |
| SCHEMBL4833148 | 0.91 | CDK4 (0.71) | CCND1CDK4CCND2CCND3FGFR1 | |
| SCHEMBL4828573 | 0.88 | CCND1 (0.66) | CCND1CDK4CCND2CCND3FGFR1 | |
| SCHEMBL29507486 | 0.88 | CCND1 (0.66) | CCND1CDK4CCND2CCND3FGFR1 | |
| SCHEMBL30176580 | 0.87 | CCND1 (0.66) | CCND1CDK4CCND2CCND3FGFR1 | |
| SCHEMBL4826720 | 0.87 | CDK4 (0.75) | CCND1CDK4CCND2CCND3FGFR1 | |
| SCHEMBL30176546 | 0.87 | CDK4 (0.75) | CCND1CDK4CCND2CCND3FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126244-A1 | COMBINATION OF ANTI-HER2 ANTIBODY AND CDK INHIBITIOR FOR TUMOR TREATMENT | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (CN) | 2023-02-08 | — | — | EP | claimed |
| EP-4126244-A1 | COMBINATION OF ANTI-HER2 ANTIBODY AND CDK INHIBITIOR FOR TUMOR TREATMENT | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |